Paloma H Giangrande Selected Research

Nucleotide Aptamers

1/2019	An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.
1/2017	Design and Preparation of Aptamer-siRNA Chimeras (AsiCs) for Targeted Cancer Therapy.
3/2016	Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL.
1/2016	Method for Confirming Cytoplasmic Delivery of RNA Aptamers.
11/2014	Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.
7/2012	Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
10/2011	Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.
7/2011	Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging.
9/2009	Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
1/2008	RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paloma H Giangrande Research Topics

Disease

26	Neoplasms (Cancer) 10/2021 - 12/2005
6	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2005
5	Prostatic Neoplasms (Prostate Cancer) 01/2016 - 08/2006
2	Macular Degeneration (Age-Related Maculopathy) 01/2021 - 09/2009
2	Ewing Sarcoma (Sarcoma, Ewing) 01/2018 - 01/2017
2	Breast Neoplasms (Breast Cancer) 09/2017 - 07/2012
2	Hyperplasia 04/2016 - 08/2007
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2016 - 01/2008
1	Glycogen Storage Disease (Glycogenosis) 01/2021
1	progressive familial intrahepatic 1 Cholestasis 01/2021
1	Body Weight (Weight, Body) 01/2021
1	Brain Neoplasms (Brain Tumor) 01/2021
1	Hypoglycemia (Reactive Hypoglycemia) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021
1	Liver Diseases (Liver Disease) 01/2021
1	Hemorrhage 10/2019
1	Multiple Organ Failure (MODS) 10/2019
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2019
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019
1	Adult-onset citrullinemia type 2 01/2019
1	Lymphoma (Lymphomas) 01/2019
1	Vascular Diseases (Vascular Disease) 04/2016
1	Thrombosis (Thrombus) 04/2016
1	Circulating Neoplastic Cells 03/2016
1	Lung Neoplasms (Lung Cancer) 03/2016
1	Carcinogenesis 11/2014
1	Hypoxia (Hypoxemia) 01/2008

Drug/Important Bio-Agent (IBA)

10	Nucleotide AptamersIBA 01/2019 - 01/2008
7	RNA (Ribonucleic Acid)IBA 01/2021 - 09/2009
5	Small Interfering RNA (siRNA)IBA 08/2017 - 08/2006
3	Messenger RNA (mRNA)IBA 01/2021 - 01/2019
3	Nucleic AcidsIBA 10/2019 - 06/2014
3	LigandsIBA 01/2019 - 07/2012
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018 - 06/2014
3	Indicators and Reagents (Reagents)IBA 03/2016 - 08/2006
2	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2017
2	Lipid NanoparticlesIBA 01/2021 - 01/2019
2	EnzymesIBA 01/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 09/2017
2	Cell Surface ReceptorsIBA 01/2016 - 08/2006
2	MicroRNAs (MicroRNA)IBA 01/2016 - 06/2014
2	AntigensIBA 11/2014 - 09/2009
2	Pharmaceutical PreparationsIBA 11/2014 - 10/2011
2	Surface Antigens (Surface Antigen)IBA 10/2011 - 07/2011
1	pegaptanib (Macugen)FDA Link 01/2021
1	Glucose-6-Phosphatase (Glucose 6 Phosphatase)IBA 01/2021
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2021
1	Starch (Cornstarch)IBA 01/2021
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 01/2020
1	Nuclear Proteins (Protein, Nuclear)IBA 10/2019
1	Blood Proteins (Serum Proteins)IBA 10/2019
1	Histones (Histone)IBA 10/2019
1	Aspartic Acid (Aspartate)FDA Link 01/2019
1	Interleukin-2 (IL2)IBA 01/2019
1	Therapeutic UsesIBA 01/2019
1	citrinIBA 01/2019
1	Amino Acid Transport System X-AG (Glutamate Transporter)IBA 01/2019
1	Codon (Codons)IBA 01/2019
1	EphA2 ReceptorIBA 01/2018
1	Nucleic Acid ProbesIBA 09/2017
1	Antiviral Agents (Antivirals)IBA 08/2017
1	Caveolin 1IBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2017
1	OligonucleotidesIBA 03/2016
1	Antineoplastic Agents (Antineoplastics)IBA 03/2016
1	TNF-Related Apoptosis-Inducing LigandIBA 03/2016
1	CaspasesIBA 03/2016
1	Apoptosis Regulatory ProteinsIBA 03/2016
1	human ERBB2 proteinIBA 07/2012
1	Trastuzumab (Herceptin)FDA Link 07/2012
1	Cisplatin (Platino)FDA LinkGeneric 07/2012
1	CopperIBA 07/2011
1	Radioisotopes (Radionuclides)IBA 07/2011
1	AcidsIBA 07/2011
1	DOTA-NHSIBA 07/2011
1	triazacyclononaneIBA 07/2011
1	Chelating AgentsIBA 07/2011
1	diamsar chelateIBA 07/2011
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 07/2011
1	N-hydroxysuccinimideIBA 07/2011
1	DiaminesIBA 07/2011
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 09/2009
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2008
1	NF-kappa B (NF-kB)IBA 01/2008
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2008
1	E2F Transcription FactorsIBA 08/2007
1	Integrin alphaVbeta3IBA 12/2005

Therapy/Procedure

16	Therapeutics 10/2021 - 08/2006
2	Liver Transplantation 01/2021 - 01/2019
2	Drug Therapy (Chemotherapy) 07/2012 - 01/2008
1	Immunotherapy 10/2021
1	Injections 01/2021
1	Stents 04/2016
1	Drug-Eluting Stents 04/2016
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 09/2009